ArticleMolecules (Basel, Switzerland)2018
High Level Expression and Purification of the Clinically Active Antimicrobial Peptide P-113 in Escherichia coli.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Emerging antimicrobial peptides in gastrointestinal disorders: Dual role in immunity and therapy.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Data-Driven Visualization of the Dynamics of Antimicrobial Peptides in Cell Death.Probiotics and antimicrobial proteins · 2025Review
- High Level Expression and Purification of Cecropin-like Antimicrobial Peptides inBiomedicines · 2022Article
- Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Design, Dimerization, and Recombinant Production of MCh-AMP1-Derived Peptide inFrontiers in fungal biology · 2021Article
- Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields.Frontiers in cellular and infection microbiology · 2021Review
- Expression of chromogranin A-derived antifungal peptide CGA-N12 inBioengineered · 2020Article
- The Interactions between the Antimicrobial Peptide P-113 and LivingInternational journal of molecular sciences · 2020Article
- Review
- Article
- A Recombinant Snake Cathelicidin Derivative Peptide: Antibiofilm Properties and Expression inBiomolecules · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
P-113, which was originally derived from the human saliva protein histatin 5, is a histidine-rich antimicrobial peptide with the sequence AKRHHGYKRKFH. P-113 is currently undergoing phase II clinical trial as a pharmaceutical agent to fight against fungal infections in HIV patients with oral candidiasis. Previously, we developed a new procedure for the high-yield expression and purification of hG31P, an analogue and antagonist of human CXCL8. Moreover, we have successfully removed lipopolysaccharide (LPS, endotoxin) associated with hG31P in the expression with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.